Podcast Episodes
Back to Search
Pharmaceutical Executive Daily: The Medicare GLP-1 Bridge
In today's Pharmaceutical Executive Daily, AlzeCure Pharma announces a collaboration with QuantumCell ApS worth more than $2.2 billion for global rig…
4 months, 2 weeks ago
Pharmaceutical Executive Daily: FDA Names Seven Participants to Precheck Program
In today's Pharmaceutical Executive Daily, FDA selects seven companies for its new PreCheck Pilot Program, Kirsten Whipple examines how the concept o…
4 months, 2 weeks ago
Pharmaceutical Executive Daily: Ipsen Enters Merger Agreement to Acquire Kartos Therapeutics
In today's Pharmaceutical Executive Daily, a pharma M&A roundup covers Ipsen's up to $1.75 billion acquisition of Kartos Therapeutics and Zymeworks' …
4 months, 2 weeks ago
Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
4 months, 3 weeks ago
Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration
In today's Pharmaceutical Executive Daily, Eli Lilly and Abbisko Therapeutics announce a new strategic research collaboration in which Abbisko will l…
4 months, 3 weeks ago
Pharmaceutical Executive Daily: FDA Pilot Targets Faster Early-Stage Drug Trial Starts
In today's Pharmaceutical Executive Daily, the FDA announces Operation TrialBlazer, a pilot program aimed at cutting early-stage clinical trial timel…
4 months, 3 weeks ago
Pharmaceutical Executive Daily: AbbVie Acquires Apogee Therapeutics for $10.9 Billion
In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding a suite of clinical-stag…
4 months, 3 weeks ago
Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010
In today's Pharmaceutical Executive Daily, an FDA advisory committee votes unanimously in favor of the benefit-risk profile of Moderna's investigatio…
4 months, 4 weeks ago
Pharmaceutical Executive Daily: FDA Approves Utebzi and Capvaxive
In today's Pharmaceutical Executive Daily, Biogen announces its second acquisition of 2026, a deal worth up to $1 billion for private immunology biot…
5 months ago
Pharmaceutical Executive Daily: Meaningfully Improving Therapy Persistence in Patient Support Programs
In today's Pharmaceutical Executive Daily, FDA staff release briefing documents flagging evidence gaps in Moderna's mRNA flu vaccine, a pharma roundu…
5 months ago